Therapeutic strategies for allergic airways diseases

Paediatric Respiratory Reviews

Volumn 5, Issue 1, 2004, Pages 45-51

  Carlsen, Kai Håkon ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Allergic rhinitis; Allergy vaccination; Asthma; Child; Combination therapy; Infant inhaled steroid; Leukotriene antagonist

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BUDESONIDE; CETIRIZINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUTICASONE; IMMUNOGLOBULIN E; KETOTIFEN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LORATADINE; MONTELUKAST; NEDOCROMIL SODIUM; PLACEBO; PSEUDOEPHEDRINE; SALMETEROL; STEROID; TRIAMCINOLONE ACETONIDE;

ADRENAL SUPPRESSION; ALLERGIC RHINITIS; ARTICLE; ASTHMA; BRONCHUS REACTIVITY; CHILD; CHILD DEVELOPMENT; CHILDHOOD DISEASE; CLINICAL TRIAL; COMORBIDITY; DISEASE CONTROL; DRUG EFFICACY; DRUG POTENTIATION; EARLY DIAGNOSIS; EXERCISE INDUCED ASTHMA; GROWTH INHIBITION; HOSPITAL ADMISSION; HUMAN; HYPOGLYCEMIA; IMMUNOTHERAPY; MEDICAL DOCUMENTATION; MEDICAL RESEARCH; NONHUMAN; PARENT; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIMARY PREVENTION; PRIORITY JOURNAL; RESPIRATORY TRACT ALLERGY; RISK ASSESSMENT; SECONDARY PREVENTION; SIDE EFFECT; SOMNOLENCE; SYMPTOMATOLOGY; TREATMENT PLANNING; VACCINATION;

EID: 1342287149     PISSN: 15260542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prrv.2003.09.010     Document Type: Review

References (98)

1. Johansson SG, Hourihane JO, Bousquet J et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy 2001; 56: 813-824.
2. Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC) [see comments]. Eur Respir J 1998: 12: 315-335.
3. Strachan D, Sibbald B, Weiland S et al. Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC). Pediatr Allergy Immunol 1997; 8: 161-176.
4. Jonasson G, Lodrup Carlsen KC, Leegaard J, Carlsen KH, Mowinckel P, Halvorsen KS. Trends in hospital admissions for childhood asthma in Oslo, Norway, 1980-95. Allergy 2000; 55: 232-239.
5. Dahl R, Bjermer L. Nordic consensus report on asthma management. Nordic Asthma Consensus Group. Respir Med 2000; 94: 299-327.
6. GINA Workshop Report, Global Strategy for Asthma Management and Prevention, 2nd edn. National Institutes of Health, 2002. NIH Publication No. 02-3659.
7. British guideline on the management of asthma. Thorax 2003; 58 (Suppl 1.): 1-94.
8. van Cauwenberge P, Bachert C, Passalacqua G et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 2000; 55: 116-134.
9. Bousquet J, van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108(5 Suppl.): S147-S334.
10. Ikura Y, Naspitz CK, Mikawa H et al. Prevention of asthma by ketotifen in infants with atopic dermatitis. Ann Allergy 1992: 68: 233-236,
11. Bustos GJ, Bustos D, Bustos GJ, Romero O. Prevention of asthma with ketotifen in preasthmatic children: a three year follow-up study. Clin Exp Allergy 1995; 25: 568-573.
12. Allergic factors associated with the development of asthma and the influence of cetirizine in a double-blind, randomised, placebo-controlled trial: first results of ETAC. Early Treatment of the Atopic Child. Pediatir Allergy Immunol 1998; 9: 116-124.
13. Carlsen KH, Leegaard J, Larsen S, Ørstavik I. Nebulised beclomethasone dipropionate in recurrent obstructive episodes after acute bronchiolitis during the first two years of life. Arch Dis Child 1988; 63: 1428-1433.
14. Lodrup Carlsen KC, Carlsen KH, Nikander K et al. Nebulized budesonide after hospitalization for recurrent bronchial obstruction in children younger than 18 months. Pediatr Allergy Immunol 2001; 12: 159-165.
15. Laitinen LA, Heino M, Laitinen A, Kava T, Haahtela T. Damage of the airway epithelium and bronchial reactivity in patients with asthma. Am Rev Respir Dis 1985; 131: 599-606.
16. Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994; 88: 373-381.
17. Bousquet J, Knari J, Dhivert H et al. Quality of life in asthma. I. Internal consistency and validity of the SF-36 questionnaire. Am J Respir Crit Care Med 1994; 149(2 Pt 1): 371-375.
18. Bousquet J, Bullinger M, Fayol C, Marquis P, Valentin B, Burtin B. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J Allergy Clin Immunol 1994; 94(2 Pt 1): 182-188.
19. Vuurman EF, van Veggel LM, Uiterwijk MM, Leutner D, O'Hanlon JF. Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann Allergy 1993; 71: 121-126.
20. O'Hanlon JF, Ramaekers JG. Antihistamine effects on actual driving performance in a standard test: a summary of Dutch experience 1989-94. Allergy 1995; 50: 234-242.
21. Stempel DA, Thomas M. Treatment of allergic rhinitis: an evidence-based evaluation of nasal corticosteroids versus nonsedating antihistamines, Am J Manag Care 1998; 4: 89-96.
22. Hughes K, Glass C, Ripchinski M et al. Efficacy of the topical nasal steroid budesonide on improving sleep and daytime somnolence in patients with perennial allergic rhinitis. Allergy 2003; 58: 380-385.
23. Pearlman DS, Lumry WR, Winder JA, Noonan MJ. Once-daily cetirizine effective in the treatment of seasonal allergic rhinitis in children aged 6-11 years: A randomized, double-blind, placebo-controlled study, Clin Pediatr 1997; 36: 209-215.
24. Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ. A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma, Clin Exp Allergy 2001; 31: 616-624.
25. Meltzer EO, Malmstrom K, Lu S, Prenner BM et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized placebo-controlled clinical trial. J Allergy Clin Immunol 2000; 105: 917-922.
26. Wilson AM, Sims EJ, Orr LC, Coutie WJ, White PS, Gardiner Q et al. Effects of topical corticosteroid and combined mediator blockade on domiciliary and laboratory measurements of nasal function in seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2001; 87: 344-349.
27. Kjellman NI. Natural course of asthma and allergy in childhood [review]. Pediatr Allergy Immunol 1994; 5(6 Suppl.): 13-18.
28. Hattevig G, Kjellman G, Björkstén B. Appearance of IgE antibodies to ingested and inhaled allergens during the first 12 years of life in atopic and non-atopic children. Pediatr Allergy Immunol 1993; 4: 182-186.
29. Gustafsson D, Sjoberg O, Foucard T, Development of allergies and asthma in infants and young children with atopic dermatitis: a prospective follow-up to 7 years of age. Allergy 2000; 55: 240-245.
30. Simons FE. Allergic rhinobronchitis: the asthma-allergic rhinitis link. J Allergy Clin Immunol 1999; 104(3 Pt 1): 534-540.
31. Vignola AM, Chanez P, Godard P, Bousquet J. Relationships between rhinitis and asthma. Allergy 1998; 53: 833-839.
32. Linna O, Kokkonen J, Lukin M. A 10-year prognosis for childhood allergic rhinitis. Acta Paediatr 1992; 81: 100-102.
33. Chanez P, Vignola AM, Vic P, Guddo F, Bonsignore G, Godard P et al. Comparison between nasal and bronchial inflammation in asthmatic and control subjects. Am J Respir Crit Care Med 1999; 159: 588-595.
34. Prieto L, Berto JM, Gutierrez V. Airway responsiveness to methacholine and risk of asthma in patients with allergic rhinitis. Ann Allergy 1994; 72: 534-539.
35. Watson WT, Becker AB, Simons FE. Treatment of allergic rhinitis with intranasal corticosteroids in patients with mild asthma: effect on lower airway responsiveness. J Allergy Clin Immunol 1993; 91 (1 Pt 1): 97-101.
36. Corren J, Harris AG, Aaronson D, Beaucher W, Berkowitz R, Bronsky E et al. Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. J Allergy Clin Immunol 1997; 100(6 Pt 1): 781-788.
37. Greiff L, Andersson M, Svensson C, Akerlund A, Alkner U, Persson CG. Effects of two weeks of topical budesonide treatment on microvascular exudative responsiveness in healthy human nasal airways. Eur Respir J 1997; 10: 841-845.
38. Crystal-Peters J, Neslusan C, Crown WH, Torres A. Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. J Allergy Clin Immunol 2002; 109: 57-62.
39. Adams RJ, Fuhlbrigge AL, Finkelstein JA, Weiss ST. Intranasal steroids and the risk of emergency department visits for asthma. J Allergy Clin Immunol 2002; 109: 636-642.
40. Carlsen KH, Larsen S, Ørstavik I. Acute bronchiolitis in infancy. The relationship to later obstructive airways disease and characterization of infants at risk. Eur J Respir Dis 1987; 70: 86-92.
41. Wennergren G, Amark M, Amark K, Oskarsdottir S, Sten G, Redfors S. Wheezing bronchitis reinvestigated at the age of 10 years. Acta Paediatr 1997; 86: 351-355.
42. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med 2000; 161: 1501-1507.
43. Martinez FD. Development of wheezing disorders and asthma in preschool children. Pediatrics 2002; 109(2 Suppl.): 362-367.
44. Kristjansson S, Berg-Kelly K, Winso E. Inhalation of racemic adrenaline in the treatment of mild and moderately severe croup. Clinical symptom score and oxygen saturation measurements for evaluation of treatment effects. Acta Paediatr 1994; 83: 1156-1160.
45. Flores G, Horwitz RI. Efficacy of β2-agonists in bronchiolitis: a Reappraisal and meta-analysis. Pediatrics 1997; 100: 233-239.
46. Sanchez I, De Koster J, Powell RE, Wolstein R, Chernick V. Effect of racemic epinephrine and salbutamol on clinical score and pulmonary mechanics in infants with bronchiolitis [see comments]. J Pediatr 1993; 122: 145-151.
47. Maayan C, itzhaki T, Ear-Yishay E, Gross S, Tal A, Godfrey S. The functional response infants with persistent wheezing to nebulized beclomethasone. Pediatr Pulmonol 1986; 2: 9-14.
48. Wennergren G, Nordvall SL, Hedlin G et al. Nebulized budesonide for the treatment of moderate to severe asthma for infants and toddlers. Acta Paediatr 1996; 85: 183-189.
49. Ilangovan P, Pedersen S, Godfrey S, Nikander K, Noviski N, Warner JO. Treatment of severe steroid dependent preschool asthma with nebulised budesonide suspension. Arch Dis Child 1993; 68: 356-359.
50. de Blic J, Delacourt C, Le Bourgeois M et al. Efficacy of nebulized budesonide in treatment of severe infantile asthma: a double-blind study. J Allergy Clin Immunol 1996; 98: 14-20.
51. McKean M, Ducharme F. Inhaled steroids for episodic viral wheeze of childhood. Cochrane Database Syst Rev 2000; CD00 1107.
52. Rotschild A, Solimano A, Sekhon HS, Massoud EA, Thurlbeck WM. Effect of triamcinolone acetonide on the development of the pulmonary airways in the fetal rat. Pediatr Pulmonol 1997; 23: 76-86.
53. Essen-Zandvliet EE, Hughes MD, Waalkers HJ, Duiverman EJ, Pocock SJ, Kerrebijn KF. Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function airway responsiveness. Am Rev Respir Dis 1992; 146: 547-554.
54. Henriksen JM, Dahl R. Effects of inhaled budesonide alone and in combination with low-dose terbutaline in children with exercise-induced asthma. Am Rev Respir Dis 1983; 128: 993-997.
55. Jonasson G, Carlsen KH, Hultquist C. Low-dose budesonide improves exercise-induced bronchospasm in schoolchildren [in process citation]. Pediatr Allergy Immunol 2000; 11: 120-125.
56. König P, Schaffer J. The effect of drug therapy on long-term outcome of childhood asthma: A possible preview of the international guidelines. J Allergy Clin Immunol 1996; 98: 1103-1111.
57. Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group [see comments]. N Engl J Med 2000; 343: 1054-1063.
58. Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group [see comments]. N Engl J Med 2000: 343: 1054-1063.
59. Doull IJM, Freezer NJ, Holgate ST, Doull IJ, Growth of prepubertal children with mild asthma treated with inhaled beclomethasone dipropiorate. Am J Respir Crit Care Med 1995; 151: 1715-1719.
60. Tinkelman DG, Reed CE, Nelson HS, Offord KP. Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic, mild to moderately severe asthma in children. Pediatrics 1993; 92: 64-77.
61. Doull IJ, Campbell MJ, Holgate ST. Duration of growth suppressive effects of regular inhaled corticosteroids. Arch Dis Child 1998: 78: 172-173.
62. Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group [see comments]. N Engl J Med 2000; 343: 1054-1063.
63. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma [see comments]. N Engl J Med 2000; 343: 1064-1069.
64. Priftis K, Everard ML, Milner AD. Unexpected side-effects of inhaled steroids: a case report. Eur J Pediatr 1991; 150: 448-449.
65. Priftis K, Milner AD, Conway E, Honour JW. Adrenal function in asthma. Arch Dis Child 1990; 65: 838-840.
66. Drake AJ, Howells RJ, Shield JPH et al. Lesson of the week: symptomatic adrenal insufficiency presenting with hypoglycaemia in children with asthma receiving high dose inhaled fluticasone propionate; commentary: exogenous glucocorticoids influence adrenal function but assessment can be difficult. BMJ 2002; 324: 1081-1083.
67. Patel L, Wales JK, Kibirige MS, Massarano AA, Couriel JM, Clayton PE. Symptomatic adrenal insufficiency during inhaled corticosteroid treatment. Arch Dis Child 2001: 85: 330-334.
68. Todd G, Dunlop K, McNaboe J, Ryan MF, Carson D, Shields MD. Growth and adrenal suppression in asthmatic children treated with high- dose fluticasone propionate. Lancet 1996; 348: 27-29.
69. Todd GRG, Acerini CL, Buck JJ, Murphy NP, Ross-Russell R, Warner JT et al. Acute adrenal crisis in asthmatics treated with high-dose fluticasone proplonate. Eur Respir J 2002; 19(6): 1207-1209.
70. Ng PC, Folk TF, Wong GW et al. Pituitary-adrenal suppression in preterm, very low birth weight infants after inhaled fluticasone propionate treatment. J Clin Endocrinol Metab 1998; 83: 2390-2393.
71. Kannisto S, Korppi M, Remes K, Voutilainen R. Adrenal suppression, evaluated by a low dose adrenocorticotropin test, and growth in asthmatic children treated with inhaled steroids. J Clin Endocrinol Metab 2000; 85: 652-657.
72. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994; 344: 219-224.
73. Verberne AA, Frost C, Duiverman EJ, Grol MH, Kerrebijr KF. Addition of salmeterol versus doubling the dose of beclomethasone In children with asthma. The Dutch Asthma Study Group. Am J Respir Crit Care Med 1998; 158: 213-219.
74. Tal A, Simon G, Vermeulen JH et al. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatr Pulmonol 2002; 34: 342-350.
75. Russell G, Williams DA, Weller P, Price JF. Salmeterol xinafoate in children on high dose inhaled steroids. Ann Allergy Asthma Immunol 1995; 75: 423-428.
76. Dowling RB, Johnson M, Cole PJ, Wilson R. Effect of fluticasone propionate and salmeterol on Pseudomonas aeruginosa infection of the respiratory mucosa in vitro. Eur Respir J 1999; 14: 363-369.
77. Kemp JP, Dockhorn RJ, Shapiro GG et al. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J Pediatr 1998; 133: 424-428.
78. Knorr B, Matz J, Bernstein JA et al. Montelukast for chronic asthma in 6-to 14-year old children: a randomized. JAMA 1998; 279: 1181-1186.
79. Knorr B, Franchi LM, Bisgaard H et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2-5 years, Pediatrics 2001; 108: E48.
80. Simons FE, Villa JR, Lee BW et al. Montelukast added to budesonide In children with persistent asthma: a randomized, double-blind, crossover study. J Pediatr 2001; 138: 694-698.
81. Cash R, Blonski J. In patients with asthma that is not well controlled with inhaled steroids, does salmeterol (Serevent) or montelulkast (Singulair) offer better symptom relief? J Fam Pract 2001; 50: 802.
82. Milgrom H, Bender B, Ackerson L, Bowry P, Smith B, Rand C. Noncompliance and treatment failure in children with asthma. J Allergy Clin Immunol 1996; 98: 1051-1057.
83. Jonasson G, Carlsen KH, Sodal A, Jonasson C, Mowinckel P. Patient compliance in a clinical trial with inhaled budesonide in children with mild asthma. Eur Respir J 1999; 14: 150-154.
84. Jonasson G, Carlson KH, Mowinckel P. Asthma drug adherence in a long term clinical trial. Arch Dis Child 2000; 83: 330-333.
85. Gallefoss F, Bakke PS. Impact of patient education and self-management on morbidity in asthmatics and patients with chronic obstructive pulmonary disease [in process citation]. Respir Med 2000; 94: 279-287.
86. Boner AL, Valletta EA. Education in asthmatic children. Monaldi Arch Chest Dis 1994; 49: 250-253.
87. Strunk RC, Mrazek DA, Fukuhara JT. Masterson J, Ludwick SK, LaBrecque JF. Cardiovascular fitness In children with asthma correlates with psychologic functioning of the child. Pediatrics 1989; 84: 460-464.
88. Carlsen KH, Carlsen KC. Exercise-induced asthma. Paediatr Respir Rev 2002; 3: 154-160.
89. Ram FS, Robinson SM, Black PN. Effects of physical training in asthma: a systematic review. Br J Sports Med 2000; 34: 162-167.
90. Rasmussen F, Lambrechtsen J, Siersted HC, Hansen HS, Hansen NC. Low physical fitness in childhood is associated with the development of asthma in young adulthood: the Odense schoolchild study. Eur Respir J 2000; 16: 866-870.
91. Castro-Rodriguez JA, Holberg CJ, Morgan WJ, Wright AL, Martinez FD. Increased incidence of asthmalike symptoms in girls who become overweight or obese during the school years. Am J Respir Crit Care Med 2001; 163: 1344-1349.
92. Barr RG, Cooper DM, Speizer FE, Drazen JM, Camargo CA Jr. Beta(2)-adrenoceptor polymorphism and body mass index are associated with adult-onset asthma in sedentary but not active women. Chest 2001; 120: 1474-1479.
93. Backman A, Belin L, Dreborg S, Halvorsen R, Malling HJ, Weeke B. Standardization of allergenic preparations. Comments with reference to the second edition of the common Nordic guidelines for registration of allergenic preparations. Allergy 1991; 46: 81-84.
94. Bousquet J, Fockey R, Malling HJ et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology [see comments]. Ann Allergy Asthma Immunol 1998: 81 (5 Pt 1): 401-405.
95. Hedlin G. The role of immunotherapy in pediatric allergic disease. Curr Opin Pediatr 1995; 7: 676-682.
96. Bousquet J, Michel FB. Specific immunotherapy in asthma. Allergy Proc 1994; 15: 329-333.
97. Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med 1995; 151: 969-974.
98. Moller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109: 251-256.